clinical research organization in dubai

Dubai, Dubai United Arab Emirates AMICULUM is an independent family of 11 branded agencies that deliver communications and consultancy services to pharmaceutical, biotechnology and health technology companies across the world. What makes us different is our agile and highly collaborative approach, which allows us to put together the right expertise from across our business to deliver high-quality, technically accurate and compelling content for different audiences, through the selective use of key communication channels. AMICULUM has grown steadily since 2001 with significant repeat business from our clients and recommendations from the leading experts we have worked with. We now have a team of over >350 healthcare communications professionals based in Europe, Asia-Pacific, MENA, and the USA.

P.O. Box 72900 Abu Dhabi United Arab Emirates Biocon Pharmaceuticals offers synthetic chemistry, molecular biology, and APIs.

Dubai HealthCare City P.O. Box 505176 Dubai United Arab Emirates Biocon Pharmaceuticals offers synthetic chemistry, molecular biology, and APIs.

Office # 205, Building C/P 72, Dubai Healthcare City, Dubai, United Arab Emirates ClinArt provides clinical project management, monitoring, quality assurance, and patient recruitment.

Dubai, Dubai United Arab Emirates Clinical Pathology Services offers histopathology, cytopathology, serology, hematology, biochemistry, and microbiology services.

32, MARASI DRIVE STREET BUSINESS BAY 177-0 DUBAI, DUBAI, 2534686829 United Arab Emirates We specialize in curating a diverse collection of specimens, primarily Formalin-Fixed Paraffin-Embedded (FFPE) blocks, enriched with a range of valuable features. Our biobank houses a meticulously cataloged assortment of FFPE blocks, each accompanied by comprehensive pathology reports along with Tumour and Necrosis Percentage. These blocks serve as a foundational resource for conducting a variety of research studies and diagnostic investigations. For those seeking a deeper understanding of genetic insights, we offer FFPE blocks with mutation analysis. These specimens undergo thorough genetic characterization, enabling researchers to delve into the intricate molecular landscape of each sample. Our cutting-edge Next-Generation Sequencing (NGS) Data Analysis further empowers investigators to uncover hidden genetic information, contributing to a more nuanced comprehension of disease mechanisms. In addition, we provide FFPE blocks that have undergone Polymerase Chain Reaction (PCR) and Fluorescence In Situ Hybridization (FISH) assays. These tested and reported specimens offer a targeted perspective, allowing researchers to explore specific genetic markers and structural alterations with high precision. One of the unique offerings of our biobank is the availability of Tissue specimens. This paired resource is a treasure trove for longitudinal studies, enabling researchers to correlate molecular changes in tissue samples with corresponding changes in plasma, offering insights into disease progression and treatment response. At our pathology lab biobank, we are committed to advancing medical and scientific knowledge by providing a range of high-quality specimens and associated data. Whether you're engaged in cancer research, biomarker discovery, or therapeutic development, our diverse collection is designed to catalyze your investigations and drive progress in the field of pathology and beyond. • We offer FFPE blocks with NGS mutation analysis. • FFPE blocks that have undergone Polymerase Chain Reaction (PCR) and Fluorescence In Situ Hybridization (FISH) assays.

Dubai, Dubai United Arab Emirates As a leading CRO, Europe, Middle East & Africa Clinical Research (EMEACR) is a dynamic full service clinical research organization in the EMEA region that has developed significant expertise to assist clients in the pharmaceutical, biotechnology and medical device industries to expedite time-to-market, in order to bring safe and effective treatments to the global marketplace for the patients who need them.

P.O. Box : 4184 - Ajman, United Arab Emirates

Executive Office No. 103, Building No. 3, 1st Floor, Dubiotech Business Centre, Academic City, Dubai United Arab Emirates Getz Pharma Research offers impurity profiling, stability testing, API, formulation development, characterization, and screening services.

United Arab Emirates Genetrics along with their partners represent a diverse set of technical and scientific capabilities. We help hospitals, research labs, universities, forensic labs, environment labs, food and drug control labs and genome centre labs to design large scale projects and provide reference testing services. We associate with leading institutions and laboratories to provide Diagnostics and Genomics Reference testing services, which include Microarray, Next Generation Sequencing (NGS) and Bioinformatics services to domestic / international pharma, biotech companies and academia.

Dubai Silicon Oasis, DDP, Building A1 Dubai, Dubai, 000000 United Arab Emirates IBS GL is a fast-growing CRO with a network of clinical sites, facilitating access to a wide range of biospecimens. Our clinical network encompasses medical doctors, research groups, hospitals, and testing labs. Our project office can assist in formulation of a technical task, and provide tailored biomaterial collections.

1318, F13, OQ3, DSP - South Tower, Dubai Science Park Dubai, Dubai, 00000 United Arab Emirates Modeling and Simulation Decisions FZ LLC is an independent modeling consultancy. Our objective is to provide model-informed drug development solutions for global pharmaceutical companies and biotech start-ups. • We support decisions-making across the entire R&D pipeline by addressing the recurring questions on compound selection, dose & regimen, therapeutic window, preclinical & clinical study design optimization, choices for combination treatments, and more. • Our team of highly qualified scientists is experts in the diverse set of quantitative techniques, including population PKPD modeling, model-based meta-analysis, quantitative systems pharmacology, joint modeling, agent-based modeling, and machine learning, with the modeling experience in various therapeutic areas, such as oncology, immuno-oncology, cardiovascular and metabolic diseases, neuroscience, respiratory and infectious diseases. • Our deep scientific and technical rigor is demonstrated in our publications, in peer-reviewed disease-domain journals.

SD2-225, Second Floor, DSP Laboratory Complex, Dubai Science Park Dubai, United Arab Emirates, 00000 United Arab Emirates Modeling and Simulation Decisions FZ LLC is an independent modeling consultancy. Our objective is to provide model-informed drug development solutions for global pharmaceutical companies and biotech start-ups. • We support decisions-making across the entire R&D pipeline by addressing the recurring questions on compound selection, dose & regimen, therapeutic window, preclinical & clinical study design optimization, choices for combination treatments, and more. • Our team of highly qualified scientists is experts in the diverse set of quantitative techniques, including population PKPD modeling, model-based meta-analysis, quantitative systems pharmacology, joint modeling, agent-based modeling, and machine learning, with the modeling experience in various therapeutic areas, such as oncology, immuno-oncology, cardiovascular and metabolic diseases, neuroscience, respiratory and infectious diseases. • Our deep scientific and technical rigor is demonstrated in our publications, in peer-reviewed disease-domain journals.

Office No: 1303, Building No: P/1341, Plot No: C-87 Electra Street, behind Honda Showroom Abu Dhabi, UNITED ARAB EMIRATES

The Offices World Trade Center Level 17, Office 1745 Central Market, Al Markaziya Abu Dhabi, United Arab Emirates At Truven Health Analytics™, our purpose is to make healthcare better — lower costs, improved quality, better results. Simple words. Yet remarkably complex concepts. But that's not stopping us. Or our customers. Every day, we get to work with smart, passionate professionals, from every facet of the industry, as they manage change and implement strategies that will achieve exactly those outcomes. Our customers are healthcare payers and providers. In both the private and public sectors. They're researchers and suppliers. Regulators. Movers and shakers in each piece and part of the healthcare world. With this broad view of healthcare, we're able to see when new challenges are just beginning to emerge. And that's when we begin working on new solutions. Data. We're driven by it. Known for our exacting collection and secure management of data, we've worked with clinical evidence, claims, clinical, and other healthcare data for more than 40 years. We know the challenges to watch for, what to do about them — and how to recognize new ones. Like finding new ways to measure risk for providers who take on more of it, and payers who contract for it. Or integrating data to deliver the solutions today's converging healthcare interests demand. Analytics. Because data alone is just numbers and letters. The need for reliable insights from data demands proven analytics. Our methodologies and algorithms are uniformly trusted across the industry to deliver critical information that leads to confident decisions. Coupled with flexible reporting, integration, and consulting services, our sophisticated analytics enable our customers to make their part of healthcare better, faster. Domain expertise. We have it. We really have walked in our customers' shoes. We've worked in their environments. That level of understanding, plus our leading data management capabilities and advanced analytics, are why our customers turn to us as their partner to deliver quality, reduce costs, and yield greater value in healthcare.

G-01, Building # 14, Dubai Internet City P.O.Box 500041, Dubai United Arab Emirates Visual Sparks Technologies offers IT solutions and clinical trial services.

Dubai, Dubai United Arab Emirates Visual Sparks Technologies offers IT solutions and clinical trial services.

Dubai Silicon Oasis Dubai United Arab Emirates Wacker offers contract manufacturing, biologic analysis, and quality control/assurance services.

Dubai, Dubai United Arab Emirates Advanta is an agronomic and vegetable seed company with a 20 year track record of success and growth. Advanta Limited is the holding company for the global business of Advanta. We have direct operations in India, Australia, Argentina and Thailand. We have exports of our products going into 25 more countries. United Phosphorous Ltd., a large Indian group in the global Agro Chemical sector, acquired Advanta in February 2006. Advanta Limited is now a member of the UPL Group of companies. In the month of April 2007 Advanta completed a very successful IPO. Advanta is now listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) in India. We have unique, superior and proprietary germplasm. This, combined with technology and bioscience capability gives us a robust platform for growth. Our experienced management team is ready to give a dynamic push to the aggressive growth plans we have. While continuing with traditional breeding principles, we have over the years successfully adopted the latest technological innovations to fast track our crop research. Dihaploid and Molecular Marker technology are some of the technologies we have successfully adopted in our crop improvement programs. We have entered into strategic alliance with some of the leading and high quality technology innovation companies across the world for value added biotech traits like pest resistance, herbicide and drought tolerance. Advanta is now embarking upon a very aggressive growth strategy. While organic growth will be a key factor in this, strategic acquisitions will play a crucial role in achieving our objectives set for the next five years.

Office 104, plot No: 258-615 Al Quoz 3rd, Dubai, UAE Akay is a leading global supplier of paprika and spice oleoresins from India.

Site Information

The Contract Research Map is owned and maintained by Scientist.com. It was created to help researchers in the life sciences identify and connect with contract research organizations (CROs) based on geography. Updated nightly, this map features all of the available CROs within our network, so you can order services with a few clicks. Click on a specific country, scroll on the map itself or type into the search bar at the top—there are many ways to find the location and suppliers that you’re looking for. From Argentina to New Zealand, use this map to connect with a CRO near you.

We believe that every researcher across the world should be able to connect with the thousands of global CROs that exist and have the opportunity to work together. Like many industries,the life science supply chain has been disrupted over the last year. But there are many other circumstances such as international customs regulations or sensitive shipping times that create limitations around which countries are feasible to partner with. Sometimes, finding a CRO based in a country that best suits your research needs is imperative. We hope this contract research map allows you to find the right partner in the right place at the right time.

Have questions or feedback? We’d love to help. You can find our FAQs and contact information on the Learn more page.

Interested in connecting with one or more of the contract research organizations listed on this map? By clicking on the company’s name, you will be directed to their supplier profile on the Scientist.com marketplace. Once you set up a marketplace account you can start the ordering process immediately.

What is Scientist.com?

Scientist.com is the world's largest enterprise marketplace for outsourced R&D services. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies.

How can I use Scientist.com?

Scientist.com has built private, enterprise marketplaces from 24 of the 30 largest pharmaceutical companies, 80+ biotech companies, the US National Institutes of Health (NIH) and numerous other pharma and biotech companies. If you are employed by one of these organizations, you can log in to get started today. If you are unsure about how to get started, you can email our team at   [email protected] or go to our website   www.scientist.com to speak to someone via our live chat.

Why should I place my order through Scientist.com?

Scientist.com is a highly efficient enterprise-wide outsourcing marketplace that makes it possible for research organizations to save time and money, access innovation and ensure compliance. It utilizes a universal legal agreement and AI technologies to enable research like never before. See how comparing proposals and getting 1-on-1 support from our Research Concierge® team will enable you to place more research today.

How do I get my organization listed on the map?

If your CRO isn’t showing up on the map, then please be sure your company profile is up to date in Scientist.com’s Backoffice. After logging in, click the Your Company button in the navigation at the top, and then select the Locations tab.

Information about my organization is incorrect, how do I fix it?

Head over to backoffice.scientist.com to update your supplier profile and information. It may take up to two business days for the updates to be reflected on the map.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Latest News

RAY CRO is pleased to announce the latest publication of an article entitled “Level of Agreement and Correlation Between the Estimated Hemoglobin A1c Results Derived by Continuous or Conventional Glucose Monitoring Systems

publication of an article entitled “Level of Agreement and Correlation Between the Estimated Hemoglobin A1c Results Derived by Continuous

Level of Agreement and Correlation Between the Estimated Hemoglobin A1c Results Derived by Continuous or Conventional Glucose Monitoring Systems Compared with the Point-of-Care or Laboratory-Based Measurements: An Observational Study

Evaluation of Patient Satisfaction and Clinical Efficacy of Using Blood Glucose Meters Featuring Color-coded Indicators in Patients with Type 1 Diabetes: An Observational Hospital-Based Study

Publication: Screening and Treatment Program to Eliminate Hepatitis C in Egypt

PDC-CRO is a full-service contract research organization offering a broad range of early to late phase drug development services managed by professionals fully devoted to the clients’ programs and needs. The services can be contracted as part of a full-service integrated program or as stand-alone customized solutions. PDC works in close partnership with our clients to maximize opportunities, while maintaining flexibility to individual requirements and delivering key milestones on time and on budget.

PDC is a regional contract research organization, founded in 2011 and offering a Full-Service End-to-End innovative Solutions for your Phase I to IV clinical trials and NIS /RWE studies in the Middle East and Africa region. PDC-CRO offers direct access to 15+ MEA countries, in line with global standards and local cultures and regulations. Our international experience, as well as our proven track record of successful trials since 2011 assures our clients that PDC-CRO is their reliable partner for the MEA region. Our partners are comprised of an elite portfolio of clients including pharmaceutical corporations, biotechnology corporations, medical devices companies, global CROs, and academic institutions. Our team consists of 100+ employees experienced in managing clinical projects from start-up to completion with a pool of expertise. PDC is currently recognized among the leaders of Clinical Research Organizations in the region.

Our Services

Providing the full range of phase i to iv clinical development services..

Pharmaceutical Development Company is a full-service Contract Research Organization, dedicated to providing Clinical Research Solutions and Services across the MEA region.

Site Management and Coordination

Health Economics

Clinical outsourcing, clinical operations, medical writing, regulatory services, data science, biostatistics, clients testimonial.

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam et, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Patient patient whose heart stopped beating for 50 minutes

Keep upto date with our blogs

January 10, 2021

The MEA region

January 18, 2021

1000 Volunteers have been enrolled

February 22, 2021

The Middle East and Africa region

March 22, 2021

For the Covid-19 Trials in the MEA region.

Mission & Value

• Sites selection
• Feasibility
• Regulatory submissions
• Project Management
• Medical Writing
• Pharmacovigilance
• Training & Quality Assurance
• Staff Outsourcing

With 140 employees and more than 300 clinical trials performed in over 35 countries, MCT is the leading CRO in MEA region (Middle-East & Africa) and Pakistan. Working with many international pharmaceutical & biotech companies from all the globe (US, Europe, Asia) we are the renowned expert of MEA and Pakistan, enabling us to guide you through each country specificities (regulatory process, patient flow, health care system) and select the best sites for your clinical trials. Our experience in clinical trials in the region is wide and unique: infectious disease (including COVID 19), tropical disease, hematology, rare disease, cardiology, oncology, diabetes … MCT is your partner of choice for MEA and Pakistan.

WHY CHOOSE US

We support our sponsors with our local expertise of MEA and Pakistan: optimized startup (site selection & regulatory submission) and site management (proximity, cultural understanding, privileged communication).

MCT is the only CRO covering the whole MEA region and Pakistan through its own staff and local offices. We have developed a unique knowledge of the filed, making MCT the EXPERT of these regions.

MCT team is very experienced at all levels: Clinical Project Leads, Regulatory Officers, CRAs. Our team is made of professionals combining international experience with local expertise. They are MCT best value, contributing every day, by their skills and knowledge, to the success of your clinical trials.

MCT spirit and value are focused on Rigor, professionalism, respect of Deadline and above all: Client satisfaction

• ICH GCP (De)
• ICH GCP (En)
• ICH GCP (Es)
• ICH GCP (Fr)
• ICH GCP (It)
• ICH GCP (Pt)
• ICH GCP (Ru)
• AUSTRALIA (NHMRC)
• JAPAN (PMDA)
• US Clinical Trials Registry
• EU Clinical Trials Registry
• Pharmaceutical Companies
• Clinical Research Labs
• Service Companies
• Clinical Research Events
• Publications
• Researchers

RAY-CRO in United Arab Emirates

Web:   https://www.ray-cro.com/

Phone:   +971525964578

• Contract research organizations
• United Arab Emirates

Dubai Science Park, Office 1004, Dubai, UAE

Other RAY-CRO's locations around the world

• Saudi Arabia

About RAY-CRO

RAY is a regional full-service contract research organization with extensive experience in the management of clinical trials across a broad range of therapeutic areas.

RAY was established in Feb 2010. Company services:

• Clinical Operations
• Clinical Data Management
• Pharmacovigilance
• Patient Support Programs
• Medical Affairs Services and Trainings
• Regulatory Affairs
• Medical Translation
• Biostatistics
• Medical Writing
• Pharmaco-economics Services
• Trainings and Workshops
• Mobile Nursing
• Quality Assurance and Auditing

List of CROs by location

• Bosnia & Herzegovina
• Czech Republic
• Netherlands
• Switzerland
• United Kingdom
• Dominican Republic
• El Salvador
• Saint Lucia
• Trinidad & Tobago
• United States
• Philippines
• South Korea
• Turkmenistan
• Burkina Faso
• Congo, DR of
• Cote d'Ivoire
• Equatorial Guinea
• South Africa
• New Zealand
• Papua New Guinea

• Verify Documents, Clients & Products
• Offices & Labs
• United Arab Emirates

Our Services

• Our Company
• Sustainability
• Insights & Resources

What are you looking for?

Some topics you might be interested in, clinical research.

As a leading Contract Research Organization (CRO) with over 40 years’ experience, we are uniquely placed to help you design, develop and implement clinical trial solutions for your projects. We help optimize your timelines cost-efficiently to bring your product to market quickly and safely. We support you with fast testing and development processes, enabling you to make safe ‘go/no go’ decisions about your product that are based on the most reliable data. As the leading biometrics CRO with a state-of-the-art Clinical Pharmacology Unit, we have the resources and expertise to support you at every step. 

As a full service CRO, we offer:

• Strategic input and consulting
• Regulatory support
• Clinical trial management and monitoring
• Data management and Electronic Data Capture (EDC)
• Biostatistics and statistical programming
• Medical writing
• Medical safety
• Data and Safety Monitoring Board (DSMB) and clinical events committees
• Clinical trial laboratory testing

We cover multiple therapeutic areas with a focus on infectious diseases, respiratory, oncology and dermatology.

To discuss your clinical research outsourcing requirements, contact us today.

Bioanalytical Solutions

Clinical & Consumer Panels

Clinical Pharmacology

Clinical Research Consultancy

Clinical Trial Laboratory Testing

Clinical Trial Management

GCP Audit Services

Medical Safety & Regulatory

Looking for something specific.

Search within Clinical Research

Site & Investigator Registration

Find out more

World leading development, bioanalysis and clinical research through one point of contact

Related links, related services, more services, news & insights.

• SGS Gulf Limited

+971 4 883 22 22

+971 4 883 24 24

SGS Building, Street no. N 203,

Jebel Ali Free Zone North,

Dubai, United Arab Emirates

• Book appointment
• Hospitals & Clinics
• Specialities
• Patient Portal

• Important notice

Mediclinic International is aware of a fake social media post that is being circulated requesting users to engage with a Medical Feedback Reward Survey. Mediclinic has not circulated any such survey. The social media post has not been published by Mediclinic. Mediclinic advises that people do not engage with the survey or respond. We release all our official communications on our website and our official social media channels .

• Mediclinic Middle East
• Stay Services & Hospitals - Mediclinic Middle East
• Clinics & Hospitals in Dubai & Abu Dhabi - Mediclinic
• Health Knowledge
• Services and Specialities
• Mediclinic Health Packages
• Careers at Mediclinic Middle East
• About Mediclinic Middle East
• Media and News
• Mediclinic Middle East - Referring Doctors
• Mediclinic Middle East - Careers at Mediclinic
• Mediclinic Middle East Special Offers
• Mediclinic Baby - Prenatal, Maternity & Antenatal Care
• Privacy Statement
• Terms of Use
• Mediclinic Emergency
• Mediclinic Middle East - Health Insurance Partners
• What you should do in an emergency

Clinical Research in The Middle East - Mediclinic

• Pharmacy Home Delivery
• Mediclinic Kids
• Mediclinic Middle East - Book an Appointment with Our Doctors
• Mediclinic Precise - Genetic Testing & Profiling
• Mediclinic at Home
• Bourn Hall Fertility Centre
• Ayadi Homecare, أيادي للرعاية الصحية المنزلية
• Quality healthcare services in the comfort of your home
• Patient Privacy Notice
• Experience Cutting-Edge Healthcare at Mediclinic UAE - Health Experience Hub
• Client Experience Hub
• Genetic Health
• Travel Clinic
• Travel Vaccination Services at Mediclinic UAE

Mediclinic Middle East is one of the very few private healthcare organisations in the UAE to actively support its clinician’s research endeavours through medical research centres in the UAE. The number of facilities at Mediclinic Middle East provides access to a wide variety of patients and therapeutic areas. MCME has established a Research office to engage research opportunities that can substantially impact patients’ wellbeing. 

The Corporate Research Office is dedicated to the following:

• Ensure that all the research projects carried out at MCME are approved by the internal Research and Ethics Committee as well as the local Regulatory Authorities prior to initiation
• Contact point for Clinical Research Organisations and sponsors
• Provide support to the MCME research teams 
• Monitor and evaluate ongoing research
• Manage clinical research project budgets
• Provide Good Clinical Practice (GCP) training to MCME Research teams
• Ensure patient safety throughout all clinical trials 

MCME Research Brochure

PDF | 1.18 MB

Research Studies

Workflow Process

Mediclinic Middle East Research Office follows specific guidelines to ensure that clinical research is carried out ethically and adds real value to the scientific community.

Our Publications

Dr. Adrian Stanley Chief Academic Officer

Dr Rakshinda Mujeeb Research Projects Manager Rakshinda.Mujeeb@mediclinic.ae

Ms. Zineb Katache   Research Assistant Zineb.katache@mediclinic.ae

Mediclinic Middle East Research Office Mediclinic Corporate Office, Dubai Production City, Publishing Pavillion, Level 6, PO Box 123812, Dubai UAE. Contact Email:  MCME-ResearchOffice@mediclinic.ae

You are using an outdated browser. Please upgrade your browser to improve your experience.

• Dubai Health
• A-Z Directory

Please choose the service you would like to log into.

Student login

Staff login, online admission.

• MBRU-Biomedical Research Center
• Undergraduate
• Postgraduate Programs
• Clinical Attachment
• Continuous Professional Development
• Scholarships
• Program Catalogs
• Student Life
• Graduate Medical Education
• Residency Admissions
• Fellowship Admissions
• Internship Admissions
• The Center for Genomic Discovery
• Research Facilities
• Research Opportunities

Learning Resources

• Al Maktoum Medical Library
• Khalaf Ahmad Al Habtoor Medical Simulation Center
• H.H Sheikh Mohammed Bin Rashid Al Maktoum
• About Dubai Health

Media Center

• Publications
• MBRU 360 Newsletter
• Clinical attachment
• H.H Sheikh Mohammed Bin Rashid Al Maktoum’s Vision
• FAQ’s

Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) and Al Jalila Foundation joined forces to develop Biomedical Research in Dubai. This partnership led to the establishment of the MBRU-Biomedical Research Center (MBRU-BRC), supported by Al Jalila Foundation. This first-of-a-kind life sciences research center in Dubai dedicates more than 950 m² of floor space to various areas of biomedical research, and it is equipped with the latest research technology. The Center also plays host to numerous researchers and postdoctoral fellows that graduated from leading institutions from across the globe. This collaboration between MBRU and Al Jalila Foundation has so far led to significant scientific discoveries and landmark publications in peer-reviewed scientific journals. The Center is located at the Mohammed Bin Rashid Medical Research Institute on the 7th floor of the Al Jalila Foundation, Building (No. 12) in Dubai Healthcare City.

• Our Leadership
• Terms & Conditions
• Privacy Policy
• Clinical Research

Accelerating drug and device development through comprehensive R&D, market access, commercialization, and regulatory support across all clinical trial phases.

Supports decentralized clinical

10 ongoing projects, multicenter multination trials, end to end management, regulatory & medical affairs support, medical tourism, expertise in specific therapy.

Insights Research Organization & Solutions (IROS) is the first UAE-based Contract Research Organization (CRO) specializing in healthcare research. From clinical trials across all therapeutic areas to integration of real-world data, we provide the highest international ethical and scientific standards in clinical trial management, as well as key insights that lead to innovative, life-changing treatments.

Other Assets

AI-driven platforms covering the entire healthcare ecosystem and creating a continuous data loop.

Built to address the need for population-scale detection and diagnosis of various infections.

Omics Centre of Excellence is invested in the accentuated power of genomic, clinical and cross- disciplinary data that enables healthcare transformation...

Pharmaceutical manufacturing hub and bio-therapeutics projects in collaboration with Tier 1 pharma giants.

Providing predictive wastewater surveillance, advanced industrial testing, and comprehensive environmental tracking and reporting services through cutti...

• Asia-Pacific
• Middle East & Africa
• The Pharma Legal Handbook
• Regulatory, Pricing and Reimbursement
• Marketing, Manufacturing, Packaging and Labeling
• Preclinical and Clinical Trials
• Op-Eds & Contributions
• White Papers

Clinical Research in the UAE: Quickfire Progress & The Road Left to Travel

With cutting-edge hospital infrastructure being put in place, government authorities rolling out evermore supportive regulatory upgrades, big pharma championing ‘clinical trial diversity’ with greater non-Caucasian representation in trial cohorts, and a high regional prevalence of genetic diseases, it seems that the stage is set for the UAE to assume a much more prominent role in global clinical research. But is it that simple, and what needs to be done next for the Emirates to truly achieve clinical trial hub status?

Challenging Beginnings

Only one percent of global clinical trials take place in the Middle East and Africa, a number which reflects neither the size of the region, the burden of illnesses that its 1.5 billion-plus population carries, or the medicines they consume. Global biopharma has traditionally situated the in-human testing of its latest molecules in the US and Europe with their large and willing patient populations, closer to headquarters, hospitals and universities with the expertise to carry out such trials, and marketplaces with the financial means to absorb any products that emerge from them.

Even in the region’s most developed markets, like the UAE, challenges abound. Mohamed Mostafa, CEO of full-service MEA-focused clinical research organisation PDC CRO notes that “the UAE’s small population size is a challenge. Additionally, most of the people here are expats, and because they are travelling here for work, they are generally in good health. Also, the population is 70 percent male, so women-specific studies or gender-diverse research becomes more challenging.”

Mostafa continues, “Having worked for Big Pharma companies, I know that headquarters’ decision making around site allocation is based on two areas: operational and strategic. Operationally we are fine in MEA, with a diverse population, rapid site activation, good infrastructure, and strong regulatory bodies. Where we struggle in most of the region is on population and commercial market size. Nevertheless, if we do have a pool of patients, like in rare diseases, it is a lot easier to convince pharmaceutical companies to partner with us here.”

MSD GCC Managing Director Ashraf Mallak adds that “There are several reasons why MSD did not have a clinical footprint in the GCC in previous years. Some of the external reasons include the need for a large population, a large number of patients to conduct trials, as well as an established research infrastructure.”

Changing Times

However, spearheaded by the UAE and its ambitious attempts to climb the biopharmaceutical value chain, there are now hopes that MEA can become a more significant contributor to global clinical research efforts.

Mallak points out that “things are changing. Last year we signed an agreement with the Department of Health of Abu Dhabi (DoH) to start exploring observational research in the UAE. We invited our Global Clinical Research Team for a visit to Abu Dhabi to assess preparedness for clinical trials which showed great promise due to the diversity of the UAE population, the high calibre of the healthcare infrastructure and institutions, the talent and competence of researchers with vast international experience as well as the regulatory environment of the UAE.”

The physicians within MEA have sufficient experience and knowledge gained from working and studying in Europe and the US, the right patient pools exist, and a good enabling infrastructure is there Hassan Herrou, CSL Behring

Hassan Herrou, general manager for MEA at CSL Behring , which holds a significant portfolio of rare diseases therapies, sees strong fundamentals in place, at least in his company’s therapeutic areas of focus. “The physicians within MEA have sufficient experience and knowledge gained from working and studying in Europe and the US, the right patient pools exist, and a good enabling infrastructure is there. Therefore, there is a fantastic opportunity for CSL Behring to take the next step and conduct more multicentre clinical trials in the region.”

Others foresee more clinical trials coming to the region as part of the UAE government’s drive to achieve life science hub status. “The next stage in the country’s life sciences development, besides being a base for regional headquarters, will be greater investment in innovation and R&D, as APAC hubs like Singapore have already done, to propel the UAE forward,” says Samir Khalil, executive director of PhRMA MEA . “When choosing where to situate a clinical trial, industry sponsors are looking for a favourable ecosystem, which I think the UAE can work on further to attract a proportion of these global trials.”

Finding the Niches

There seems to be broad stakeholder alignment that, with a population of under 10 million, the UAE must focus in on specific niches to compete as a trial destination. “While the population is relatively small, the UAE could be a base for late-stage trials, which have a strong medical impact as well as an impact on employment and the overall economy,” says Khalil.

The Dubai Science Park’s Senior Vice President Marwan Abdulaziz Janahi continues, “We are seeing a growing number of late-stage clinical trials being carried out in the UAE, with the aim of providing access to treatments. This is particularly true for rare diseases, as the Middle East has a higher percentage of patients affected by such diseases than other regions. Several established pharmaceutical companies are investing in rare disease treatments, with companies such as AstraZeneca, which recently acquired Alexion, seeking to identify and treat patients in the region as part of their market access strategy. This is a highly positive trend.”

We are seeing a growing number of late-stage clinical trials being carried out in the UAE Marwan Abdulaziz Janahi, Dubai Science Park

PDC CRO, which predominantly focuses on infectious diseases, metabolic disorders, and rare conditions, has been able to count on support from the authorities to fuel its clinical research output, especially in the paediatric space. “We have a lot of expertise in genetic, haematological, and neurological disorders, with the majority being paediatric-related,” notes Mohamed Mostafa. “It is especially important that these younger patients are diagnosed early as quick access to therapies gives them a big advantage later in their lives. This is all being fuelled by the government and the Al Jalila Hospital, the leading paediatric hospital in the UAE. We have even been able to conduct trials that involve patients from outside the UAE by having them referred for treatment here.”

Mostafa adds that “many of the trials we do here are extremely complex. The region is typically considered to be a rescue region, as when companies cannot find patients across the world they come here as a last resort. This means we are well prepared and are ready for simpler clinical trials in the future.”

Regulatory Upgrades

An ecosystem of supportive policies and regulations will be crucial if the UAE is to take the next step in its development towards clinical trial hub status. Positive steps have already been taken in this direction, as Mohamed Ezz Eldin, who heads up Novartis operations in the Gulf region , notes.

We have worked hard to ensure our regulatory framework fosters innovation and progress, whilst maintaining exceptional standards of quality and safety Noura Al Ghaithi, Abu Dhabi DoH

“For a country to attract more R&D investments in areas like clinical trials, it is important to have a supporting regulatory framework to encourage private sector involvement,” says Ezz Eldin. “The UAE is attracting experts to the country by having the right infrastructure in place, collaborating with universities and institutes, and setting up clinical trial centres which will strengthen its position as a clinical trial centre in the region.

PDC CRO’s Mostafa is in accordance, adding that “the UAE government, particularly the Abu Dhabi DoH, has accelerated the development of clinical studies. They have overseen what we are doing and appreciate the importance of building a legitimate ecosystem that meets international regulations.”

The Abu Dhabi DoH’s own undersecretary, Noura Al Ghaithi , proclaims that “We have worked hard to ensure our regulatory framework fosters innovation and progress, whilst maintaining exceptional standards of quality and safety. This has included streamlining the approval process for clinical trials. It takes no longer than 28 days between trial submission and approval which has led us to see a rapid expansion in clinical trials, with a staggering increase in the number of clinical trials conducted locally between 2021 and 2022 – an increase year-on-year of 484 percent.”

The COVID Push

The COVID-19 pandemic and the subsequent rush to test therapeutics and vaccines in record time also had a big effect on the way in which the UAE, and the wider region, conducts and approaches clinical research. “During the pandemic, we adjusted approval timelines to be part of global clinical trials to develop vaccines in collaboration with the US, China, and Russia,” says the Dubai Science Park’s Abdulaziz Janahi. “In just two years, we streamlined our regulatory process, making it more robust and efficient, creating a strong foundation to accelerate innovation.”

COVID-19 was a massive catalyst for growth which has made people understand the importance of research Mohamed Mostafa, PDC CRO

PDC CRO has seen its own business as an outsourcing partner for clinical research booming post-pandemic. “COVID-19 was a massive catalyst for growth which has made people understand the importance of research,” states Mostafa.

“Our clinical studies within this area have given confidence to pharmaceutical and biotechnology companies to conduct more research and partner with us in the region,” he says. “We partner now with many top 20 pharmaceutical global players through master services agreements or partnerships. Also, we have direct access to biotechnology companies and support them in their programs of clinical development through Phases I, II and III, with clients from the US, Europe, and Asia Pacific.”

While admirable progress has already been made in boosting the UAE’s clinical research output, there remains a long road to travel before the country can call itself a true global heavyweight in the field. For Abdulaziz Janahi, the ultimate goal for the UAE is becoming more than just a global node in the drug development process of innovations emanating from abroad, but instead bringing its own products to market.

“We need to focus on pushing ideas that are being developed at local universities from the lab bench to the market,” he says. “This is a long-term objective that cannot be achieved overnight, as it requires the development of capabilities and talent. I believe this will take place within the next five to ten years but is crucial to take the right measures to ensure it does so.”

Patrick Burton

Related articles, uae enabling innovation in the uae: incentives, regulatory policies & ip rights protection, uae middle eastern sovereign wealth funds continue pharma investment push, uae the long read: the uae – raising its game, latest report.

Related Content

Other topics.

See our Cookie Privacy Policy Here

• Employee Self Service

Change Color

• Strategic Priorities & Objectives
• Laws & Legislations
• Centre of Excellence
• Organ Donation
• Primary Care
• Medical Education
• Coronavirus - COVID -19
• Medical Tourism
• Research and Innovation Center
• Professionals
• Abu Dhabi Health Workforce Masterplan
• Scope of Practice
• Policies & Manuals
• Lists & Tools
• Medications & Supplements Awareness Material
• Jawda - Quality Metrics
• Unified Healthcare Professional Qualification Requirements (PQR)
• Health Information Exchange standards

Healthcare facilities are required to complete the Training Programme on Abu Dhabi Healthcare Guidelines for Health Media & Advertising System as mentioned in circular number 26/2023, for more information Click Here

DOH urges all healthcare and pharmaceutical facilities & Health professional to Adhere to the circular number(63\2021) by updating the details of the mobile number & e-mail address in order to receive all circulars & letters issued by DOH, for more information Click Here

• PDC – Pharmaceutical Development Company
• Ray - Contract Research Organization
• IQVIA Connected Intelligence
• IROS - Insights Research Organization & Solutions
• CTI Clinical Trials and Consulting
• MCT- CRO FZ-LLC
• Phoenix Clinical Research SAL (Offshore)

Subscribe for updates

Thanks for subscribing, last updated: 31 aug 2024.

• [email protected]
• Head Office - Beirut

Clients & Partners

We are proud to manage some of the leading global and regional brands.

Phoenix Clinical Research is a regional dynamic full-service Contract Research Organization (CRO) established in Lebanon. Its objective is to cover the whole Middle East and North Africa region.

Our Services

A full service regional Contract Research Organization.

Medical Writing & Biostatistics

Whether you need support in clinical and observational studies or communications...

Project Management

We ensure that our project managers have the proper knowledge and skills to successfully manage your...

Clinical Operations

On most of the projects we have managed in the Middle East region, we have developed specific recruitment...

Pharmacovigilance

A short description of the service and how the visitor will benefit from it.

Why Phoenix CR?

Phoenix Clinical Research is one of the very few full service CROs in the MENA region that is ISO accredited.

Phoenix Clinical Research combines the flexibility and responsiveness of its structure coupled with more than 18 years of international and regional expertise.

Phoenix CR was the first Clinical Research Organization (CRO) to monitor a Phase I study in Egypt.

Our team helped rescue several clinical trials in the region after handover from other international and regional clinical research organizations (CROs).

We are very known for the quality of our deliverables as we aim to bring the Swiss standards to the Middle East.

Have a Look at Our Latest News

Provided by Department of Health – Abu Dhabi, Innovative Gene Transfer Therapy Administered For Duchenne Muscular Dystrophy for First Time in Abu Dhabi

  Department of Health – Abu Dhabi (DoH) has provided revolutionary gene transfer therapy for Duchenne muscular dystrophy for the first time in the emirate. The treatment was carried out at Sheikh Khalifa Medical City (SKMC), part of SEHA, a subsidiary of PureHealth, reflecting Abu

ILIKOS Consulting Group and PHOENIX Clinical Research Announce Strategic Partnership

As the timeframe to develop a new therapy or technology is increasing along with competitive and high-risk nature of the industry, exploring emerging regions that offer better Patient access while maintaining regulations and standards for clinical research has become a necessity. Entering new regions is

Challenges of the MENA region and how we overcome them

Challenges of the MENA region and how we overcome them Conducting clinical trials in the Middle East and North Africa (MENA) region offers a multitude of opportunities, yet it also presents unique challenges that biotech companies must carefully navigate. Understanding and effectively addressing these challenges

Why MENA Region

• Ideal to conduct genetic studies with high rates of consanguinity that could reach 70% in certain regions.
• Western lifestyle habits increased the prevalence of cancer, cardiovascular and metabolic diseases.
• GCC countries have the second highest prevalence of type 2 diabetes worldwide.
• It has the highest incidence of pulmonary infections in the world.
• Study start-ups can be achieved in less than three months in some countries.
• The majority of investigators and study site staff are fluent in English.
• Many Middle Eastern hospitals have been granted the Joint Commission International Accreditation.
• The increase in life expectancy.

© 2024 All Rights Reserved. Design by Pixelated

For Individuals

• Rehabilitation
• Specialized Treatment Programs

For Corporates

• Employees Assistance Program (EAP)
• Smoking Cessation Program
• Stress Debriefing & Critical Incident Stress Management
• Training & Awareness Programs

For Health Professionals

• Continuous Medical Education
• Patient Referral
• Our Clinicians
• Health Education Center

Clinical Research

• Latest ACPN Media Mentions
• Patient Experience

الخط الساخن:   800 ACPN[2276]

• Dr. Taoufik Alsaadi (ACPN, Chair)
• Prof. George Tadros (ACPN, Vice-Chair)
• Mr. Ahmed Mostafa (ACPN)
• Ms. Rana Abounakad (ACPN)
• Dr. Saqib Latif (ACPN)
• Dr. Tarek Shahrour (Sheikh Khalifa Medical City)
• Dr. Ahsan Khandoker (Khalifa University)
• Dr. Khaled Kadry (Maudsley Health Abu Dhabi)
• Dr. Lamya Turkawi (Sheikh Khalifa Medical City)
• Ms. Hajir Elbarrawy (ACPN)
• Ms. Reem Suliman (ACPN)

3. Research Collaborations:

a. Academic and Scientific Research Institutions:

Khalifa University, Abu Dhabi

Zayed University, Abu Dhabi

New York University Abu Dhabi

Harvard Medical School Center for Global Health Delivery – Dubai

Imperial College London Diabetes Centre (ICLDC) – Abu Dhabi

b. Current Pharmaceutical supporters

Biogen, Inc®

4. Guidelines for Proposed Research Studies:

No restrictions on the type of research that can be conducted as long as:

• Goal is justified and implications are identified
• Ethical considerations are met and conduct complies with guidelines of ICH – GCP and DOH Standard Operating Procedures (SOPs)
• Principal investigator meets requirements and has expertise in the study field

Note on clinical trials:

• Products/drugs must be registered with:
• The Ministry of Health Drug Control Department and DOH Medical Products Regulation Section
• Application fees apply

Note: investigational medicinal product is one that has been given marketing authorization but is being investigated for uses other than what is indicated. Does not apply to Phase 1 trials.

5. Criteria for Research:

Proposed studies must meet the following criteria: Benefit:  Does the proposed study have clear benefits to the community in which it is conducted? Effectiveness:  Will the study be effective in achieving the desired goal? Necessity:  Is the study necessary to achieve the goal or is there an alternative that won’t infringe on a competing value? Proportionality:  Is the desired goal important enough to justify overriding another principle or value? Least infringement:  Is the study designed to minimize infringement on the values that conflict with it? Transparency:  Is the Primary Investigator prepared to publicly justify their decision?

6. Ethical Considerations:

Ethics regarding human subjects: Respect for persons:  respect autonomous choices; protect those lacking autonomy Obtain informed consent from those capable of giving consent, proxy consent Beneficence:  do not harm; maximize benefits, minimize harms Risk/benefit assessment is conducted, clear action if adverse effects arise Justice:  fairness in distribution; treat equals equally Recruitment of subjects is fair, vulnerable populations not simply targeted out of convenience

7. Research Ethics Application: What to include

• ACPN ethics review application form  ( download form )
• Detailed study protocol  ( download form )
• Questionnaires and description of drugs/products that will be used (Arabic and English)
• Subject consent form (Arabic and English)
• Subject information sheet (Arabic and English)
• CVs of all investigators
• Investigators’  certification of Research Ethics Training for Protecting Human Research Participants

8. Application Submission Procedures:

• All ethics proposals are submitted to the IRB coordinator ( [email protected] ) , who reviews the application for completeness and confirms to investigators within five days of its receipt
• The IRB is required to give an ethical opinion on an application within 60 calendar days of the receipt of a valid application. Where the IRB considers that further information is required in order to give an opinion, the IRB may make one request in writing for further information from the applicant. The period of 60 days will be suspended pending receipt of this information
• In the case of a clinical trial involving a medicinal product for somatic cell therapy, the normal statutory time limit for review is extended to 90 days. This may be extended by a further 90 days (i.e. to 180 days in total) where the REC needs to consult a specialist group or Committee about the application

9. Ongoing Clinical Research Studies:

• Observational study to collect information on the safety and drug utilization of Fampyra® – Dr. Taoufik Alsaadi and colleagues
• A Pilot study on the prevalence of depression and anxiety among neurology patients attending ACPN – Dr. Ahmed Mohamed and colleagues
• Narcolepsy in the UAE: A Case series – Dr. Khaldoun Mozahem and colleagues
• Real world retrospective study of effectiveness and safety of Gilenya (Fingolimod®) in relapsing remitting Multiple Sclerosis in the Middle East and North Africa (FINOMENA) – Dr. Taoufik Alsaadi
• Repetitive Transcranial Magnetic Stimulation (rTMS) in the treatment of major depressive disorders: results from the UAE – Ms. Seada Kassie and Dr. Taoufik Alsaadi
• A comparison study of the use of Haptic Handwriting Tool among children with learning difficulties in the UAE – Dr. Samra Tahir and Dr. Mohamad Eid
• Can combined endurance and resistance training slow disease progression in adults with relapsing remitting multiple sclerosis? A pilot study – Ms. Helen Hughes and colleagues
• A cohort study on treatment outcome of anorexia nervosa in the UAE – Ms Carine El Khazen and colleagues
• Investigating the role of sleep-disordered breathing and its treatment on depressive symptoms in the UAE – Dr. Khaldoun Mozahem and colleagues
• Antiepileptic drugs use and major congenital malformation rate: A prospective observational cohort study: The United Arab Emirates – Dr. Taoufik Alsaadi and colleagues
• Patient cost-sharing for ambulatory neuropsychiatric services in Abu Dhabi, UAE  – Dr. Yousef Abouallaban and colleagues
• Potential factors impacting health-related quality of life among patients with epilepsy: Results from the United Arab Emirates  – Dr. Taoufik Alsaadi and colleagues
• Depression and anxiety as determinants of quality of life in patients with multiple sclerosis: The United Arab Emirates – Dr. Taoufik Alsaadi and colleagues
• Suicidal ideation Is associated with altered variability of fingertip photo-plethysmogram signal in depressed patients – Dr. Yousef Abouallaban and colleagues
• The rapidly changing landscape of multiple sclerosis immunomodulatory therapy a retrospective chart review in The United Arab Emirates  – Dr. Taoufik Alsaadi and colleagues
• Impact of working memory and cognitive functioning on specific language impairment (SLI)  – Dr. Samra Tahir and colleagues
• Working memory in children with intellectual disability (ID)  – Dr. Samra Tahir and colleagues

For more information, please send an email to  [email protected] or call +(971-2)-492-6000.

Board Members

Dr. Taoufik Alsaadi

Prof. George Tadros

ACPN offers quality mental health services with utmost care

Therapeutic Expertise

Participate

Explore end-to-end solutions throughout development — from portfolio optimization and regulatory strategy, to Phase I-IV clinical trials, market access planning, and more.

• Portfolio management and asset valuation
• Early development and innovation
• Integrated clinical development
• Approval and access
• Value substantiation lifecycle management

HOW WE DO IT

• Delivery models
• Operational excellence
• Medical affairs
• Building patient insights into assets, profile and claims
• Portfolio optimization
• Asset valuation and indication prioritization
• Early evidence review
• Model-based drug development
• Integrated development strategy and planning
• Phase I Clinical Trials
• Proof of Concept Studies: Phase IB-IIA
• Patient Engagement Strategy and Enrollment Solutions
• Patient Inclusion
• Site Alliance Network and KOL Engagement
• Protocol Optimization
• Regulatory Strategy
• Market Access Strategy and Delivery
• Biomarker and Genomic Medicine Strategy
• Clinical Trial Supply & Logistics
• Medical Communications
• Phase IIB-IV Clinical Trials
• Operationalize post-trial access with a proven platform approach
• Protocol-Driven, Customized Site Solution Strategy
• Regulatory Strategy, Submissions, Compliance, and Outsourcing
• Clinical Development Technology Optimization
• Real World Evidence
• Global Regulatory Submissions and Outsourcing
• Compliance and Risk Management
• Real-World Evidence, Market Access Strategy and Planning
• Regulatory Compliance, Drug Safety and Pharmacovigilance
• Lifecycle Optimization
• Gain an advantage through FSP
• Leveraging AI and digital in clinical development

Parexel Biotech provides the end-to-end capabilities you’ll need to succeed. We're fast, flexible, and dedicated to impacting patient lives.

Utilize our expertise across therapeutic areas, combining innovative trial designs, leading clinical and regulatory expertise, global reach, and a passion for changing patient lives.

• Neuroscience
• General medicine
• Infectious disease & vaccines
• Inflammation & immunology

Cross-Therapeutic Expertise

• Cell & gene therapies
• Rare diseases

Our experts help you stay at the forefront of the industry - and ahead of change.

New Medicines, Novel Insights

• Advancing precision oncology
• Advancing rare disease drug development
• Accelerating development of cell and gene therapies
• Achieving patient-guided drug development

Discussions on Diversity

• Chapter 1 Bridging the Gap
• Chapter 2 Beyond the Binary

The Regulatory Navigator

• Gene therapy: are high costs and manufacturing complexities impeding progress?
• New FDA draft guidance: Implications for simplifying interchangeability for biosimilars in the US
• Key implications for nonclinical development: FDA guidance on human gene therapy products incorporating human genome editing

Latest Report

New Medicines, Novel Insights: Advancing precision oncology

Thinking about joining a clinical trial? Learn the drug development process, what it’s like to participate, how to find a trial, and answers to frequently asked questions.

INTERESTED IN PARTICIPATING?

• Healthy Volunteers
• Patient Volunteers
• Patient Advocacy Groups

HEAR FROM REAL PATIENTS

• Patient Stories

TRIAL SITES

Want to collaborate with us to offer clinical trials at your site? We would welcome the opportunity to discuss.

We are one of the largest CROs in the world, speeding life-changing medicine to market by engaging patients With Heart ™. Learn about who we are, what we do, and what we believe.

• Leadership team
• Global reach
• Our DE&I strategy
• Compliance, tax & privacy
• Meet us at an event
• Board of Directors
• Our ESG strategy
• Compliance & Ethics
• Tax Strategy
• Privacy Policy
• Cookies and other web tracking
• Supplier Data Privacy Requirements
• Terms of Use
• French Gender Pay Data
• UK Gender Pay Data
• UK Modern Slavery Act Statement
• Data Privacy Framework
• Supplier Diversity Policy

What can we help you find today?

The perspectives and opinions expressed in this material represent those of the patient advocate only and should not be considered a solicitation, promotion or advertisement for any services of Parexel, or any drugs or therapies, including those under development. Participating in clinical trials for investigational medicines offers patients potential benefits, such as access to cutting-edge treatments and expert medical care, while contributing to medical research. However, risks may include side effects, unpredictable outcomes, and time commitment. Careful assessment of these factors helps patients make informed decisions. The content of this material, including graphics, images and text, is provided for informational purposes only and does not constitute medical advice, diagnosis or treatment. Please consult your healthcare professional for medical advice. The patient advocate has provided their consent for the use and distribution of this content.

Patient Story

Rare Diseases

• Inflammation & Immunology

Cell & Gene Therapy

While running a triathlon, andrea stumbled and realized something was wrong..

Her condition worsened. Within months, she was forced to walk with a cane.

Then, finally, came the diagnosis.

She thought it was just an injury. Her hamstrings were tight, and her body felt stiff and slow.

She had als, a condition affecting more than 200,000 people around the world., her life expectancy was shortened to just two to five years — but she was determined to make the most of it., andrea continued to join triathlons, even as she underwent treatment in a clinical trial, inspiring many and raising $1,000,000 for als research., today, alive beyond her original prognosis, she serves on our patient advisory council, using her experiences to help improve our neuroscience trials., lives can change when you design neuroscience trials with speed and precision..

• Utilize the right experts, with the right specialization
• Find the patients you need and earn their trust
• Satisfy global regulations to get your treatment to patients safely and quickly
• Design studies and endpoints with market access in mind

What we do, we do

Our Experts

Our neuroscience specialists collaborate to get your treatment to patients faster.

MORE EXPERTS

Antal János, M.D., M.B.A.

Vice President, Glob...

Karla Kanis, M.D.

Mohit Verma, M.D.

Global TA Section He...

Andreas Lysandropoulos, M.D., Ph.D.

Senior Vice President, Global Neuroscience Therapeutic Area Head

With 15+ years of experience as a clinical neurologist, principal investigator, and medical leader, Andreas works with you to create an effective development strategy. Once the plan is in place, he and his team lead all aspects of execution — ensuring your assets are approved quickly and efficiently.

"For me, ‘With Heart’ means with passion and empathy. It is my mission to gather people around a common cause and inspire everybody to reflect on and be passionate about what we do together because it matters to patients who rely on us all for a better life."

Our diverse neuroscience experiences ensure you get the expertise you need across all indications of neurology and psychiatry.

Innovative trial designs allow us to optimize your trials for maximum impact.

Neuroscience sites around the world allow us to accelerate study startups.

• North America
• South America
• Middle East & Africa

Advanced modeling and simulation allow us to predict drug effects ahead of time, saving time, money, and resources.

And our patient-first approach results in deeper, more relevant insights for trial design and execution.

BENEFITS MAY INCLUDE

What can we do to help you change patient lives?

See neuroscience capabilities Visit all therapeutic areas Explore neuroscience careers

Discover other patient stories

Sara's only symptom was fatigue. But after some routine tests, she was diagnosed with breast cancer.

When Austin was 3 years old, his parents realized something was wrong. Multiple falls, concussions, and a broken arm led to a diagnosis.

Tina had lost her father to Crohn's disease. Now she faced her own diagnosis — and it derailed her life.

One night, while watching TV with her husband, Robyn felt a lump in her neck. As a doctor, she knew the risk.

We focus on patients, because they inspire us to deliver better trials, faster than ever . So we can make a difference for more patients everywhere.

Who we are,, parexel is proudly among the world’s largest clinical research organizations.

A dedicated CRO providing the full range of Phase I to IV clinical development services  and leveraging the breadth of our clinical, regulatory and therapeutic expertise , our team of more than 21,000 global professionals works in partnership with biopharmaceutical leaders and sites to design and deliver clinical trials with patients in mind , to make clinical research a care option for anyone, anywhere.

Clinical Research Coordinator (Contractor)

Position description.

We are seeking a clinical research coordinator (CRC) to join the Clinical Genetics Branch (CGB) of the Division of Cancer Epidemiology and Genetics (DCEG) at the National Cancer Institute (NCI). The CRC fills a critical role for the interprofessional research team, ensuring compliance with protocol and overall clinical objectives and managing priorities to ensure accurate data collection/entry, data systems management, and data reporting for clinical protocols.  

Major responsibilities include:

• Participate in study coordination and ensure that study activities follow established protocols and Standard Operating Procedures (SOPs), and utilize approved forms, templates and practices. 
• Enter data into research databases, systems, and applications for ongoing studies. 
• Assist the research team with extrapolation, entry, cleaning, and overall quality assurance of incoming and historical data.
• Assist with managing and retrieving data from the Clinical Research Information System at the NIH Clinical Center, dissemination of surveys, and data collection from participants.
• Assist with managing submissions for branch protocols to the Institutional Review Board (IRB), ensuring compliance with IRB requirements and deadlines, and maintaining regulatory files and documentation.
• Format and enter data into spreadsheets and online platforms to analyze information and create reports.
• Assist researchers with developing, completing, and maintaining study data collection forms and source documents.
• Document, collect, record, and retain all research-related participant encounters including in-person, phone, or electronic in the research record (e.g., source documents, case report forms) according to regulations, guidelines, and institution-specific policies, thus ensuring good documentation practices. 

Qualifications

• A bachelor’s degree in a scientific or health-related field.
• Ability to work independently and function within a team with strong attention to detail.
• Reliable and able to prioritize competing responsibilities. 
• Two (2) years of related experience in clinical research strongly preferred.
• Experience with ServiceNow, Qualtrics, or Medidata platforms.

Organization Description

The NCI is an exciting place to work, and the position provides excellent learning opportunities and possibilities for professional advancement. Pay is commensurate with qualifications and includes a comprehensive benefit package. This is a full-time, Level 1 contract position at a government agency in Rockville, Maryland.

How to Apply

Please send a resume and cover letter via email addressing your qualifications for the position to Dr. Sadie Hutson with “Clinical Research Coordinator Application” in the subject line. The position will remain open until it is filled.

DHHS, NIH, and NCI are Equal Opportunity Employers

The NIH and NCI are dedicated to building a diverse community in its training and employment programs and encourage the application and nomination of qualified women, minorities, and individuals with disabilities. NIH provides reasonable accommodations to applicants with disabilities. If you require reasonable accommodation during any part of the application and hiring process, please notify us. The decision on granting reasonable accommodation will be made on a case-by-case basis.

A dedicated CRO in Dubai, UAE

Our Experience

Our team has developed the necessary experience to ensure successful implementation of our clinical studies.

You need to enable JavaScript to run this app.